Literature DB >> 12237284

The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis.

Urszula Bugajska1, Nikolaos T Georgopoulos, Jennifer Southgate, Peter W M Johnson, Pierre Graber, John Gordon, Peter J Selby, Ludwik K Trejdosiewicz.   

Abstract

BACKGROUND: The tumor necrosis factor (TNF) superfamily of ligands and receptors mediates immune cell survival. Some members possess a death domain, a protein motif that functions to transmit apoptotic signals, whereas others, such as CD40, do not. CD40 is expressed by both normal and malignant epithelial cells. To investigate the functional significance of this expression, we studied the effects of ligation of CD40, Fas, and TNF receptors (TNFRs) on the proliferation and survival of normal and malignant human urothelial cells and urothelial cells with disabled p53 function.
METHODS: Normal and malignant human urothelial cells were cultured with soluble TNF family agonists (CD40 ligand [CD40L], TNF-alpha, anti-Fas antibody, or cocultured with mouse fibroblasts stably transfected with plasmids that caused the cells to constitutively express CD40L or CD32; cell proliferation was estimated by an [(3)H]thymidine incorporation assay, and apoptosis was determined by Annexin V staining and by a DNA fragmentation assay. Messenger RNA levels for CD40 and potential downstream effector molecules were quantified by polymerase chain reaction-based and ribonuclease protection assays, respectively, and nuclear factor (NF) kappaB nuclear translocation was detected by immunofluorescence. All statistical tests were two-sided.
RESULTS: Soluble trimeric CD40L inhibited the growth of normal and malignant urothelial cells but did not induce apoptosis. Cell surface-presented CD40L induced massive apoptosis in CD40-positive transitional cell carcinoma cells but not in normal urothelial cells. Normal cells underwent CD40L-mediated apoptosis only in the presence of other TNFR agonists. An agonistic anti-CD40 antibody presented on the surface of CD32-transfected fibroblasts also induced apoptosis in transitional cell carcinoma cells and in normal urothelial cells. Apoptotic responses of tumor (but not normal) cells to soluble agonists were enhanced by blocking protein synthesis. Karyotypically normal urothelial cells with disabled p53 function underwent apoptosis during coculture with CD40L-expressing fibroblasts alone but were not additionally sensitive to additional TNFR agonists.
CONCLUSIONS: Susceptibility to CD40 ligation-induced apoptosis may be a novel mechanism for eliminating neoplastically transformed urothelial cells. Loss of CD40 expression may be an important adaptive mechanism for transitional cell carcinoma development and progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237284     DOI: 10.1093/jnci/94.18.1381

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  An in vitro Co-culture System for the Activation of CD40 by Membrane-presented CD40 Ligand versus Soluble Agonist.

Authors:  Khalidah Ibraheem; Christopher J Dunnill; Myria Ioannou; Albashir Mohamed; Balid Albarbar; Nikolaos T Georgopoulos
Journal:  Bio Protoc       Date:  2018-07-05

2.  CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.

Authors:  Taha Elmetwali; Peter F Searle; Iain McNeish; Lawrence S Young; Daniel H Palmer
Journal:  Mol Cancer       Date:  2010-03-08       Impact factor: 27.401

3.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

4.  The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas.

Authors:  Pauline G Knox; Clare C Davies; Marina Ioannou; Aristides G Eliopoulos
Journal:  J Cell Biol       Date:  2011-01-31       Impact factor: 10.539

5.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

6.  Multifunctional CD40L: pro- and anti-neoplastic activity.

Authors:  Aleksandra Korniluk; Halina Kemona; Violetta Dymicka-Piekarska
Journal:  Tumour Biol       Date:  2014-08-13

7.  Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Authors:  Ihab Abd-Elrahman; Taher Nassar; Noha Khairi; Riki Perlman; Simon Benita; Dina Ben Yehuda
Journal:  Oncogene       Date:  2020-10-30       Impact factor: 9.867

Review 8.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

9.  Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.

Authors:  I Airoldi; S Lualdi; S Bruno; L Raffaghello; M Occhino; C Gambini; V Pistoia; M V Corrias
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

10.  Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder.

Authors:  S A Hussain; R Ganesan; L Hiller; P G Murray; M M el-Magraby; L Young; N D James
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.